These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9838985)

  • 1. Identification of acute porphyria: evaluation of a commercial screening test for urinary porphobilinogen.
    Deacon AC; Peters TJ
    Ann Clin Biochem; 1998 Nov; 35 ( Pt 6)():726-32. PubMed ID: 9838985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening tests in acute porphyria.
    Lamon JM; Frykholm BC; Tschudy DP
    Arch Neurol; 1977 Nov; 34(11):709-12. PubMed ID: 911234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening tests for porphobilinogen are insensitive. The problem and its solution.
    Schreiber WE; Jamani A; Pudek MR
    Am J Clin Pathol; 1989 Nov; 92(5):644-9. PubMed ID: 2816816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A sensitive method of screening for urinary porphobilinogen.
    Buttery JE; Chamberlain BR; Beng CG
    Clin Chem; 1989 Dec; 35(12):2311-2. PubMed ID: 2591048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Best practice guidelines on first-line laboratory testing for porphyria.
    Woolf J; Marsden JT; Degg T; Whatley S; Reed P; Brazil N; Stewart MF; Badminton M
    Ann Clin Biochem; 2017 Mar; 54(2):188-198. PubMed ID: 27555665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid-chromatographic assay of urinary porphobilinogen.
    Jamani A; Pudek M; Schreiber WE
    Clin Chem; 1989 Mar; 35(3):471-5. PubMed ID: 2920415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Hoesch and the Watson-Schwartz tests for urinary porphobilinogen.
    Pierach CA; Cardinal R; Bossenmaier I; Watson CJ
    Clin Chem; 1977 Sep; 23(9):1666-8. PubMed ID: 890911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reliability of the porphobilinogen screening assay.
    Buttery JE; Carrera AM; Pannall PR
    Pathology; 1990 Oct; 22(4):197-8. PubMed ID: 2091000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid quantitative method using spin columns to measure porphobilinogen in urine.
    Roshal M; Turgeon J; Rainey PM
    Clin Chem; 2008 Feb; 54(2):429-31. PubMed ID: 18223134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct and simultaneous determination of 5-aminolaevulinic acid and porphobilinogen in urine by hydrophilic interaction liquid chromatography-electrospray ionisation/tandem mass spectrometry.
    Benton CM; Couchman L; Marsden JT; Rees DC; Moniz C; Lim CK
    Biomed Chromatogr; 2012 Aug; 26(8):1033-40. PubMed ID: 22740490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mass spectrometric characterisation of a condensation product between porphobilinogen and indolyl-3-acryloylglycine in urine of patients with acute intermittent porphyria.
    Marcos J; Ibañez M; Ventura R; Segura J; To-Figueras J; Pozo OJ
    J Mass Spectrom; 2015 Jul; 50(7):929-37. PubMed ID: 26349648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Hoesch test: bedside screening for urinary porphobilinogen in patients with suspected porphyria.
    Lamon J; With TK; Redeker AG
    Clin Chem; 1974 Nov; 20(11):1438-40. PubMed ID: 4425514
    [No Abstract]   [Full Text] [Related]  

  • 13. A LC-MS/MS method for the specific, sensitive, and simultaneous quantification of 5-aminolevulinic acid and porphobilinogen.
    Zhang J; Yasuda M; Desnick RJ; Balwani M; Bishop D; Yu C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(24):2389-96. PubMed ID: 21783436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks.
    Sardh E; Harper P; Andersson DE; Floderus Y
    Eur J Intern Med; 2009 Mar; 20(2):201-7. PubMed ID: 19327613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative measurement of porphobilinogen in urine by stable-isotope dilution liquid chromatography-tandem mass spectrometry.
    Ford RE; Magera MJ; Kloke KM; Chezick PA; Fauq A; McConnell JP
    Clin Chem; 2001 Sep; 47(9):1627-32. PubMed ID: 11514396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a commercially available rapid urinary porphobilinogen test.
    Vogeser M; Stauch T
    Clin Chem Lab Med; 2011 Sep; 49(9):1491-4. PubMed ID: 21627493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary excretion of porphyrins, porphobilinogen and δ-aminolaevulinic acid following an attack of acute intermittent porphyria.
    Marsden JT; Rees DC
    J Clin Pathol; 2014 Jan; 67(1):60-5. PubMed ID: 23908454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the Watson-Schwartz screening method for porphobilinogen reliable?
    Buttery JE
    Clin Chem; 1995 Nov; 41(11):1670-1. PubMed ID: 7586565
    [No Abstract]   [Full Text] [Related]  

  • 19. Quantification of Urine and Plasma Porphyrin Precursors Using LC-MS in Acute Hepatic Porphyrias: Improvement in Routine Diagnosis and in the Monitoring of Kidney Failure Patients.
    Poli A; Manceau H; Nguyen AL; Moulouel B; Dessendier N; Talbi N; Puy H; Junot C; Gouya L; Schmitt C; Lefebvre T
    Clin Chem; 2023 Oct; 69(10):1186-1196. PubMed ID: 37608428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of the porphyrin precursors delta-aminolaevulinic acid (ALA) and porphobilinogen (PBG) in the acute attack of porphyria.
    Kramer S; Becker D; Viljoen D
    S Afr Med J; 1973 Sep; 47(38):1735-8. PubMed ID: 4270402
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.